ResearcherOkayama UniversityNo recent work listed
Ken Hirao
Matched on OpenAlex author ID A5073146676. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2011: 1 paper · 2012: 1 paper
Papers 2
- Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.009↗
- A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensit… Co-author DOI 10.1007/s10147-011-0237-z↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Koichiro Tsutsumi · 2 shared papers, 2011–2012 · strength 0.05
- Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
- Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
- Hirofumi Kawamoto · 2 shared papers, 2011–2012 · strength 0.05
- Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
- Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
- Hironari Kato · 2 shared papers, 2011–2012 · strength 0.05
- Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
- Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
- Kazuhide Yamamoto · 2 shared papers, 2011–2012 · strength 0.05
- Paper Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemoth… DOI 10.1016/j.pan.2012.07.009↗
- Paper A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II stud… DOI 10.1007/s10147-011-0237-z↗
- Kazuhiro Nouso · 1 shared paper, 2012 · strength 0.03
- Hiroyuki Okada · 1 shared paper, 2012 · strength 0.03
- Ryo Harada · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.